Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Desogestrel | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Desogestrel. |
| Megestrol acetate | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Megestrol acetate. |
| Levonorgestrel | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Levonorgestrel. |
| Medroxyprogesterone acetate | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Medroxyprogesterone acetate. |
| Norethisterone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Norethisterone. |
| Estradiol | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Estradiol. |
| Ethynodiol diacetate | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Ethynodiol diacetate. |
| Mifepristone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Mifepristone. |
| Norgestimate | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Norgestimate. |
| Ethinylestradiol | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Ethinylestradiol. |
| Drospirenone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Drospirenone. |
| Cyproterone acetate | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Cyproterone acetate. |
| Gestodene | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Gestodene. |
| Dienogest | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Dienogest. |
| Norethynodrel | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Norethynodrel. |
| Norgestrel | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Norgestrel. |
| Gestrinone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Gestrinone. |
| Lynestrenol | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Lynestrenol. |
| Ormeloxifene | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Ormeloxifene. |
| Chlormadinone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Chlormadinone. |
| Norgestrienone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Norgestrienone. |
| Quingestanol | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Quingestanol. |
| Demegestone | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Demegestone. |
| Nomegestrol acetate | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Nomegestrol acetate. |
| Estetrol | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Estetrol. |
| Sucralfate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Sucralfate. |
| Bentoquatam | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Bentoquatam. |
| Kaolin | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Kaolin. |
| Aluminum hydroxide | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum hydroxide. |
| Magaldrate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Magaldrate. |
| Potassium alum | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Potassium alum. |
| Aluminum chloride | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum chloride. |
| Aluminum sulfate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum sulfate. |
| Bentonite | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Bentonite. |
| Aluminium acetoacetate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium acetoacetate. |
| Hydrotalcite | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Hydrotalcite. |
| Aluminium glycinate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium glycinate. |
| Aloglutamol | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aloglutamol. |
| Montmorillonite | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Montmorillonite. |
| Aluminium phosphate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium phosphate. |
| Aluminum chlorohydrate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum chlorohydrate. |
| Dihydroxyaluminum sodium carbonate | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Dihydroxyaluminum sodium carbonate. |
| Aluminum oxide | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum oxide. |
| Mestranol | The therapeutic efficacy of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when used in combination with Mestranol. |